Study: NCT03095638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersible dolutegravir 5 mg tablet
Description: Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dolutegravir 25 mg tablet
Description: Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.